 |
| Acute Repetitive Seizures Market Growth |
Acute repetitive seizures, also known as acute recurrent seizures refer to two
or more unprovoked seizures occurring over a period of 24 hours without
restoration of full consciousness between seizures. These are generally caused
due to abrupt cessation of anti-seizure medications, toxic–metabolic
abnormalities, central nervous system infections or head injuries. Acute
repetitive seizures can be life-threatening if not treated immediately.
Medications like benzodiazepines are used for terminating the acute repetitive
seizure episodes. Epilepsy drugs are also administered for preventing
recurrence. Advancements in treatment options such as buccal midazolam and
intranasal treatment are driving the acute repetitive seizures market.
The global acute repetitive seizures
market is estimated to be valued at US$ 7.12 Bn in 2024 and is expected to
exhibit a CAGR of 12.% over the forecast period from 2024 to 2031.
Advances in treatment such as easy to administer
buccal and intranasal formulations which deliver drugs quickly are fueling market
growth. For instance, buccal midazolam was developed to easily administer
midazolam during acute seizures without requiring intravenous access.
Key Takeaways
Key players operating in the Acute
Repetitive Seizures Market Growth are Neurelis, Inc., Bausch Health
Companies Inc., Alexza Pharmaceuticals, Inc., VERITON PHARMA, UCB S.A., Takeda
Pharmaceutical Company Limited, Pfizer Inc., Sanofi, GSK plc, Eisai Co., Ltd.,
H. Lundbeck A/S, Cognizance Biomarkers, LLC. Neurelis' intranasal midazolam
spray VALTOCO was the first FDA approved treatment for this indication.
New product launches and acquisitions are shaping the market. In 2021, Bausch
Health launched SYMPAZAN for Lennox-Gastaut syndrome and Cognizance Biomarkers
launched BIX epilepsy blood test. Also, UCB has expanded its portfolio by
acquiring Zogenix, developer of anti-seizure drug FINTEPLA.
Regions like North America and Europe dominate the global market currently due
to high healthcare spending and developed medical infrastructure. However,
Asian countries are expected to provide lucrative growth opportunities owing to
increasing healthcare awareness and improving medical facilities.
Market Drivers
- Rising incidence of epilepsy and other neurological disorders leading to
seizures is a major growth driver. According to World Health Organization,
around 50 million people worldwide have epilepsy.
- Increasing research funding for developing more effective drugs will also
fuel the market growth. Several new molecular entities and drug delivery
technologies are in pipeline which could gain approvals soon.
Market Restrains
- Strict regulations for approval of acute repetitive seizure drugs can hamper
market growth. For example, FDA demanding additional clinical trials data for
review and approval.
- High costs associated with treatment and unaffordability in low-income
regions can restrain market revenue in those areas. Also, lack of awareness in
remote areas is a challenge.
Segment Analysis
The acute repetitive seizures market is dominated by the drug therapy segment.
The increasing prevalence of epilepsy has raised demand for anti-seizure drugs
therapeutics to effectively manage the condition. Moreover, inadequate efficacy
of surgical techniques along with high costs associated with medical devices
and non-drug therapies has driven growth of drug therapy segment. Established
drugs like benzodiazepines, anti-convulsants, etc. continue to witness
increasing adoption due to their pharmacological effectiveness in controlling
seizures. However, emergence of novel advanced therapeutics with improved
safety profiles is expected to bolster segmental growth during forecast period.
Global Analysis
North America holds the largest share in global acute repetitive seizures
market owing to presence of major market players, robust healthcare
infrastructure, and increasing funding for neurological disorder research.
Favorable reimbursement scenario for treatment options along with rising
awareness levels regarding epileptic disorders has augmented regional market growth.
Asia Pacific is anticipated to emerge as the fastest growing regional market
and highest CAGR during forecast period. Factors such as increasing healthcare
expenditure, rising geriatric population prone to neurological conditions, and
growing initiatives to boost epilepsy diagnosis and management are fueling
regional opportunities. Moreover, untapped potential of emerging countries and
ongoing clinical trials for advanced therapies promises lucrative prospects for
APAC acute repetitive seizures industry.
Get More Insights On This Topic: Acute
Repetitive Seizures Market